Salmeterol/fluticasone propionate (50/250 μg) combination is superior to double dose fluticasone (500 μg) for the treatment of symptomatic moderate asthma

被引:0
|
作者
Bergmann, KC
Lindemann, L
Braun, R
Steinkamp, G
机构
[1] Allergie & Asthmaklin, D-33175 Bad Lippspringe, Germany
[2] Clin Res, Hannover, Germany
关键词
asthma; fluticasone; salmeterol; inhaled corticosteroids; lung function; quality of life; treatment;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Questions under study: if patients with asthma remain symptomatic in spite of chronic treatment with inhaled corticosteroids (ICS), increasing the ICS dosage or adding another drug to the treatment regimen are possible therapeutic alternatives. We compared the efficacy and safety of combined salmeterol fluticasone therapy (SFC, 501250 mug twice daily) with twice the dose of fluticasone propionate (FP, 500 mug b.i.d.) in symptomatic asthmatics. Methods: this prospective, double-blind study was conducted in 76 study centres. 365 symptomatic patients with moderate asthma aged >18 years and receiving ICS in a dose equivalent to 1,000 mug beclomethasone propionate per day were randomly assigned to receive either salmeterol xinafoate (50 mug) and fluticasone propionate (250 mug) in a single dry powder inhaler (Diskus(R)) or 500 mug FP twice daily. The primary efficacy endpoint was morning peak expiratory flow rate (PEFR). Secondary measurements included forced expiratory volume in 1 second (FEV1), asthma symptom scores, and use of rescue medication. Results: combined salmeterol fluticasone therapy resulted in significantly greater improvements in PEFR and symptom control than doubling the dose of FP. At week 12, morning PEFR had increased by 52 L/min from baseline in patients on SFC and by 36 L/min in subjects receiving FR The adjusted difference between groups was 16.6 L/min (95% confidence interval, 1.1 to 32.0 L/min). In the SFC group, the percentage of symptom-free days increased from baseline by 49% of days as compared with 38% of days after FP (adjusted difference: 12.6% of days, 95 % Cl 4.0 to 20.7). Quality of life improved to a greater degree after SFC therapy, and patients regarded study drugs as superior to their previous asthma medication. Adverse event profiles were similar between groups. Conclusions: the combination of salmeterol 50 mug and fluticasone 250 mug in a single dry powder inhaler was superior to twice the dose of FP (500 mug). It seems justified to add salmeterol rather than increasing the ICS dose if symptomatic asthmatics require supplementary therapy.
引用
收藏
页码:50 / 58
页数:13
相关论文
共 50 条
  • [41] Comparative efficacy of combination of fluticasone and salmeterol; fluticasone, salmeterol and montelukast; fluticasone, salmeterol, and levocetirizine in moderate persistent asthma: A study of 120 patients
    Gupta, Sandeep
    Kansal, Amrit P.
    Kishan, Jai
    CHEST, 2007, 132 (04) : 512S - 512S
  • [42] FLUTICASONE PROPIONATE/FORMOTEROL FUMARATE COMBINATION THERAPY IS AS EFFECTIVE AS FLUTICASONE PROPIONATE/SALMETEROL XINAFOATE IN THE TREATMENT OF ASTHMA: A RANDOMISED CONTROLLED TRIAL
    Bodzenta-Lukaszyk, A.
    Dymek, A.
    Mansikka, H.
    THORAX, 2010, 65 : A152 - A153
  • [43] Effects of regular treatment with combination of salmeterol/fluticasone propionate and salmeterol alone in cough variant asthma
    Tagaya, Etsuko
    Kondo, Mitsuko
    Kirishi, Saori
    Kawagoe, Michi
    Kubota, Noriyuki
    Tamaoki, Jun
    JOURNAL OF ASTHMA, 2015, 52 (05) : 512 - 518
  • [44] Initiation of maintenance treatment with salmeterol/fluticasone propionate 50/100μg bd versus fluticasone propionate 100μg bd alone in patients with persistent asthma:: Integrated analysis of four randomised trials
    Barnes, N. C.
    Jacques, L.
    Goldfrad, C.
    Bateman, E. D.
    RESPIRATORY MEDICINE, 2007, 101 (11) : 2358 - 2365
  • [45] Combination Therapy Salmeterol/Fluticasone Versus Doubling Dose of Fluticasone in Children With Asthma
    Vaessen-Verberne, Anna A. P. H.
    van den Berg, Norbert J.
    van Nierop, Jan C.
    Brackel, Hein J. L.
    Gerrits, Gerardus P. J. M.
    Hop, Wim C. J.
    Duiverman, Eric J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 182 (10) : 1221 - 1227
  • [46] Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled with fluticasone propionate 250 μg administered twice daily
    Busse, W
    Koenig, SM
    Oppenheimer, J
    Sahn, SA
    Yancey, SW
    Reilly, D
    Edwards, LD
    Dorinsky, PM
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2003, 111 (01) : 57 - 65
  • [47] Asthma exacerbations in African Americans treated for 1 year with combination fluticasone propionate and salmeterol or fluticasone propionate alone
    Bailey, William
    Castro, Mario
    Matz, Jonathan
    White, Martha
    Dransfield, Mark
    Yancey, Steve
    Ortega, Hector
    CURRENT MEDICAL RESEARCH AND OPINION, 2008, 24 (06) : 1669 - 1682
  • [48] Salmeterol/fluticasone propionate combination product in asthma - An evaluation of its cost effectiveness vs fluticasone propionate - Foreword
    Stempel, DA
    PHARMACOECONOMICS, 1999, 16 : U6 - U7
  • [49] First-line therapy with fluticasone propionate/salmeterol combination product provides superior asthma control versus montelukast or fluticasone propionate alone
    Dorinsky, PM
    Crim, C
    Yancey, S
    Edwards, L
    Rickard, K
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2002, 109 (01) : S252 - S252
  • [50] Control of mild to moderate asthma over 1-year with the combination of salmeterol and fluticasone propionate
    Lundbäck, B
    Rönmark, E
    Lindberg, A
    Jonsson, AC
    Larsson, LG
    Pétavy, F
    James, M
    RESPIRATORY MEDICINE, 2006, 100 (01) : 2 - 10